 February 10, 2026

This financing not only set a new record for Cascade in terms of single-round funding but also highlighted the capital market's recognition of the R&D team's "strong technical expertise and differentiated pipeline" in the fields of nuclear receptors and GPCR.

 January 21, 2026

Leveraging vast volumes of professional literature from both Chinese and international sources, physicians can utilize the DeepSearch feature not only to access the latest frontier guidelines across various specialty fields promptly but also to employ AI tools for literature review, significantly saving time and effort in information gathering and organization.

 January 30, 2026

On January 30, CSPC Pharmaceutical and AstraZeneca have entered into a strategic collaboration and license agreement with a potential total value of $18.5 billion to develop innovative long-acting peptide medicines. The partnership will leverage CSPC's proprietary sustained-release delivery technology and AI-driven peptide discovery platforms.

 February 10, 2026

With leading Chinese innovative drug companies and multinational corporations (MNCs) continuing to expand their presence in the small nucleic acid therapeutics sector, this field has now entered the core track of innovative drug R&D. In the future, major developments in this area are expected to emerge successively.